CALQUENCE® (acalabrutinib) ELEVATE-RR and ASCEND Data

12 Views

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Published Apr 12, 2025

Please see full Prescribing Information: https://qr.short.az/CalquenceUSPI
This video is intended for US healthcare professionals only.

Shou Ma, MD, PhD, discusses the results of ELEVATE-RR and ASCEND, two Phase 3 head-to-head trials in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

Topics include a study overview of the ASCEND and ELEVATE-RR trial, including efficacy and safety results, and personal experience with CALQUENCE.

Indication and Select Safety Information
CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions (≥30%) are diarrhea, upper respiratory tract infection, headache, musculoskeletal pain, lower respiratory tract infection, and fatigue. The most common Grade 3 or 4 laboratory abnormalities (≥10%) are absolute neutrophil count decreased, absolute lymphocyte count decreased, platelets decreased, and hemoglobin decreased.